29/01/2019 - 13:35

PharmAust secures data bonanza from Elanco

29/01/2019 - 13:35

Bookmark

Save articles for future reference.

PharmAust has signed an agreement with US pharmaceutical heavyweight Elanco that allows the biotech company to reference certain safety and blood chemistry data that were generated for the regulatory approval of Monepantel in Australia, New Zealand and the EU, as an anti-parasitic drug in livestock animals. This could potentially expedite the early proof of principle phase two trials of the anti-cancer drug in dogs.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options